Individualized medicine is the ultimate aim of many medical specialties. Attempts to individualize psychopharmacology have focused on the genetic polymorphisms of neurotransmitter- and CNS-related genes. While there have been numerous reports on the discovery of possible genetic differences in various psychiatric disorders, clinical psychopharmacology has not yet significantly benefited from such data. At present, individualized psychopharmacology in practice is still largely the choice of drugs with the least side effects for a particular patient.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/pme.10.33 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of a checklist for cognitive assessment requirements (CARE) based on a Delphi consensus study.
Sci Rep
January 2025
Department of Psychology, University of Oregon, Eugene, OR, USA.
Situational factors can influence cognitive performance and should be considered for conducting cognitive assessments. The objective of this project was to develop a checklist for Cognitive Assessment Requirements (CARE) to identify these situational factors before conducting cognitive assessments and account for them. This study employed a four-round Delphi approach involving 22 experts to identify situational factors that can impact cognitive assessment results.
View Article and Find Full Text PDFReal-time mechanism-based interventions for daily alcohol challenges: Protocol for ecological momentary assessment and intervention.
Digit Health
January 2025
Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany.
Background: Advancing evidence-based, tailored interventions for substance use disorders (SUDs) requires understanding temporal directionality while upholding ecological validity. Previous studies identified loneliness and craving as pivotal factors associated with alcohol consumption, yet the precise directionality of these relationships remains ambiguous.
Objective: This study aims to establish a smartphone-based real-life intervention platform that integrates momentary assessment and intervention into everyday life.
Objectives: Should a young person receive psychotherapy or medication for their depression and on what evidence do we base this decision? In this paper, we test the factors across modalities that may influence comparability between medication and psychotherapy trials.
Methods: We included 92 randomised controlled trials (RCTs) of psychotherapy and medication for child and adolescent depression (mean age 4-18 years). Using meta-analyses, we compared (a) participant characteristics and (b) trial characteristics in medication and psychotherapy trials.
Maternal Cannabis Use During Pregnancy and Neuropsychiatric Adverse Outcomes During Childhood and Early Adult Life.
J Clin Psychiatry
January 2025
Department of Psychiatry, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India, Department of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences, Bangalore, India
Cannabis use during pregnancy is increasing; the study of adverse outcomes in cannabis-exposed pregnancies is therefore important. Previous articles in this series described increased risks of maternal adverse outcomes, fetal adverse outcomes, birth defects in newborns, and autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) in childhood. This article examines neuropsychiatric adverse outcomes in offspring gestationally exposed to cannabis.
View Article and Find Full Text PDFD dopamine / mu opioid receptor interactions in operant conditioning assays of pain-depressed responding and drug-induced rate suppression, and a conditioned place preference procedure: assessment of therapeutic index in male Sprague Dawley rats.
Psychopharmacology (Berl)
January 2025
Department of Psychology, University of New England, Biddeford, ME, USA.
Rationale And Objectives: In vivo receptor interactions vary as a function of behavioral endpoint, with key differences between reflexive and non-reflexive measures that assess the motivational aspects of pain and pain relief. There have been no assessments of D dopamine agonist / mu opioid receptor (MOR) agonist interactions in non-reflexive behavioral measures of pain. We examined the hypothesis that D/MOR mixtures show enhanced effectiveness in blocking pain depressed behaviors while showing decreased side effects such as sedation and drug reward.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!